Marion Merrell Dow
Harley Tennison is retiring from his post as Marion Merrell Dow/USA president on Jan. 15, but will continue as a consultant to the company. Tennison, formerly with Marion for 13 years, was the top executive in the pharmaceutical area for the combined firm. Continuing the company's consolidation, David Roche, president of the prescription products division of Marion Merrell Down/USA, and John Dishaw, president of the consumer products division, will now report directly to Marion Merrell Down Exec VP/Chief Operating Officer David Sharrock.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.